PMID- 31340617
OWN - NLM
STAT- MEDLINE
DCOM- 20190801
LR  - 20200717
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 40
IP  - 6
DP  - 2019 Jun 14
TI  - [HLA-10/10 matched unrelated donor versus sibling donor hematopoietic stem cell 
      transplantation for adult acute myeloid leukemia].
PG  - 460-466
LID - 10.3760/cma.j.issn.0253-2727.2019.06.003 [doi]
AB  - Objective: To evaluate the outcomes of human leukocyte antigen (HLA) matched 
      unrelated donor hematopoietic stem cell transplantation (MUD-HSCT) for adult 
      acute myeloid leukemia (AML) in a single center. Methods: Consecutive adult AML 
      who received MUD-HSCT in our center from January 2008 to April 2017 were studied 
      retrospectively, comparing with patients undergoing matched sibling donor (MSD) 
      -HSCT in the same period. The rates of overall survival (OS) , disease free 
      survival (DFS) , relapse, non-relapse mortality (NRM) , engraftment, acute and 
      chronic graft-versus-host disease (aGVHD and cGVHD) were analyzed. Results: A 
      total of 247 consecutive cases were enrolled, including 46 patients with MUD-HSCT 
      and 201 with MSD-HSCT. All the patients experienced neutrophil engraftment except 
      for one patient who died early in the MSD group, but the median day of 
      engraftment was longer in the MUD group (15.0 vs 14.0, P=0.017) . The 
      accumulative engraftment rate of platelet was comparable between the two groups 
      (93.5%vs 98.0%, P=0.128) . The accumulative incidences of aGVHD (50.0%vs 46.3%, 
      P=0.421) and cGVHD (37.8%vs 43.0%, P=0.581) were not statistically different 
      between the two groups. Compared with the MSD group, the accumulative NRM rate 
      at+36 months after transplantation was significantly higher in the MUD group 
      (22.0%vs 10.4%, P=0.049) , while the relapse rate was not statistical difference 
      (20.5 vs 28.3%, P=0.189) . Both the 3-year OS (61.6%vs 63.3%, P=0.867) and DFS 
      (57.5%vs 61.6%, P=0.760) were comparable between the two groups. Four independent 
      risk factors were confirmed by the multivariate analysis: patient age >/=45 years 
      old, CR2 or NR before transplantation, a history of extramedullary infiltration 
      and the occurrence of grade Ⅲ-Ⅳ aGVHD. No statistical differences were 
      demonstrated in the survival rate between MUD-and MSD-HSCT in different 
      subgroups. Conclusions: The outcomes, such as GVHD, relapse, OS and DFS, were 
      comparable between MUD-and MSD-HSCT for adult AML, but higher incidence of NRM 
      and longer time to neutrophil engraftment in the MUD group. MUD-HSCT is practical 
      and feasible for adult AML who are lack of MSD.
FAU - Yao, J F
AU  - Yao JF
AD  - Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, 
      China.
FAU - Zhang, G X
AU  - Zhang GX
FAU - Shen, Y Y
AU  - Shen YY
FAU - Zhang, R L
AU  - Zhang RL
FAU - He, Y
AU  - He Y
FAU - Wei, J L
AU  - Wei JL
FAU - Jiang, E L
AU  - Jiang EL
FAU - Yang, D L
AU  - Yang DL
FAU - Feng, S Z
AU  - Feng SZ
FAU - Han, M Z
AU  - Han MZ
LA  - chi
GR  - 81670171, 81700166/National Natural Science Foundation of China/
GR  - 18JCZDJC34400/Tianjin Research Program of Application Foundation and Advanced 
      Technology/
GR  - 2016-I2M-3-023/CAMS Innovation Fund for Medical Sciences/
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Graft vs Host Disease
MH  - HLA Antigens
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Leukemia, Myeloid, Acute/therapy
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Siblings
MH  - Unrelated Donors
PMC - PMC7342396
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Hematopoietic stem cell transplantation
OT  - Sibling donor
OT  - Unrelated donor
EDAT- 2019/07/26 06:00
MHDA- 2019/08/02 06:00
PMCR- 2019/06/01
CRDT- 2019/07/26 06:00
PHST- 2019/07/26 06:00 [entrez]
PHST- 2019/07/26 06:00 [pubmed]
PHST- 2019/08/02 06:00 [medline]
PHST- 2019/06/01 00:00 [pmc-release]
AID - cjh-40-06-460 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2019.06.003 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2019 Jun 14;40(6):460-466. doi: 
      10.3760/cma.j.issn.0253-2727.2019.06.003.